In August 2018, Dewayne Johnson, a 46-year-old former groundskeeper from California, won a jury verdict against Monsanto (now owned by Bayer) in the amount of $289 million for personal injury and punitive damages. Johnson claimed that his years of exposure to Roundup, the widely used herbicide containing glyphosate, caused his non-Hodgkin’s lymphoma, a type of blood cancer. The jury unanimously agreed that Monsanto had failed to warn users about the product’s cancer risk and had acted with malice in suppressing safety research. This landmark verdict became one of the most significant herbicide-related lawsuits in American legal history and opened the floodgates for thousands of similar claims.
Johnson’s case was notable not just for its size but for the evidence presented showing internal Monsanto documents suggesting the company knew about potential cancer risks but chose not to disclose them to consumers. The verdict sent shockwaves through the agricultural industry and changed how companies approach product liability for widely used chemicals. The impact of Johnson’s case extended far beyond his personal recovery. It demonstrated that juries would hold major corporations accountable for health risks allegedly linked to their products, even when regulatory agencies like the EPA had maintained that glyphosate was safe. The case also highlighted the tension between regulatory approval and liability in court, a distinction that remains important for anyone considering whether they might have a claim related to herbicide exposure.
Table of Contents
- Who Was Dewayne Johnson and How Did He Develop His Case?
- The Evidence and Why the Jury Found Monsanto Liable
- The $289 Million Breakdown and What It Meant
- How This Case Influenced the Larger Roundup Litigation
- Important Limitations and What Claimants Need to Know
- The Role of Scientific Evidence and Expert Testimony
- The Bayer Settlement and Current Status of Roundup Claims
Who Was Dewayne Johnson and How Did He Develop His Case?
Dewayne Johnson worked as a groundskeeper and pest management professional at a california school district for many years, regularly spraying roundup to control weeds on school grounds. According to trial testimony, Johnson mixed and applied the herbicide several times per week, often without proper protective equipment or warnings about potential long-term health risks. In 2014, at age 42, Johnson was diagnosed with non-Hodgkin’s lymphoma, an aggressive cancer affecting the lymph nodes and immune system. After his diagnosis, Johnson began researching Roundup’s safety profile and discovered scientific studies linking glyphosate exposure to cancer risk—studies that Monsanto had allegedly worked to discredit.
Johnson’s legal team, led by attorneys Aimee Wagstaff and others at Miller & Zois, built a case that emphasized Monsanto’s knowledge and negligence. They presented evidence that the company had funded studies designed to counter independent research, had influenced regulatory decisions, and had actively suppressed warnings about potential carcinogenic effects. Johnson became the first person to take such a case to trial and win, paving the way for similar claims that would follow. His willingness to pursue the case despite being a relatively ordinary person—not a celebrity or public figure—made the verdict resonate with other individuals who believed they had been similarly harmed.
The Evidence and Why the Jury Found Monsanto Liable
The jury’s decision in Johnson’s case rested heavily on internal company documents that emerged during discovery, showing that Monsanto executives had discussed cancer concerns and had worked to influence scientific research and regulatory processes. The evidence presented included emails and memos suggesting Monsanto knew about potential health risks but chose not to warn consumers or include safety information on product labels. This “malice” element—the suggestion that the company knowingly withheld information—was crucial to the jury awarding the substantial punitive damages component of the verdict.
Notably, the jury’s finding differed from regulatory determinations made by agencies like the EPA and the International Agency for Research on Cancer, which had different conclusions about glyphosate’s safety. This discrepancy highlights a critical limitation: a jury verdict does not overturn regulatory approval or government safety determinations. The jury was evaluating whether Monsanto should have warned consumers based on the scientific information available and what the company knew, not whether glyphosate is definitively carcinogenic. Even after Johnson’s verdict, regulatory agencies in the United States continued to maintain that glyphosate could be used safely when applied according to label instructions—a warning that, in Johnson’s case, the jury found was inadequate given what the company knew.
The $289 Million Breakdown and What It Meant
The $289 million verdict consisted of compensatory damages and punitive damages. Compensatory damages are intended to cover Johnson’s actual losses: medical expenses, lost wages, pain and suffering, and reduced life expectancy. Punitive damages, the larger component, are meant to punish the defendant and deter similar conduct by other corporations. The jury determined that a punitive component was warranted because of Monsanto’s reckless disregard for Johnson’s safety and its efforts to conceal information about potential risks.
In practical terms, the $289 million verdict meant that Johnson would receive compensation for his illness and suffering, but the actual amount he received was less than the headline number. The verdict was appealed and eventually reduced through judicial modifications and settlement discussions. When Bayer (which had acquired Monsanto) settled the broader class of Roundup-related claims in 2020, Johnson’s case was incorporated into that larger settlement framework. For individuals following similar cases, understanding that verdicts often decrease through appeals and post-trial motions is crucial—the announced figure rarely matches the final payout.
How This Case Influenced the Larger Roundup Litigation
Following Johnson’s victory, Monsanto (and later Bayer) faced a tsunami of similar lawsuits. Thousands of people who had used Roundup or had occupational exposure filed claims alleging that glyphosate caused their cancers. The first verdict created a precedent that influenced settlement strategies, jury expectations, and the types of evidence that would be persuasive in future cases. Bayer, facing potential exposure running into tens of billions of dollars, eventually decided that settling was preferable to fighting each case individually.
In June 2020, Bayer agreed to a global settlement of approximately $10.9 billion to resolve tens of thousands of Roundup-related lawsuits and to end future claims related to glyphosate and cancer. This settlement did not mean that Bayer admitted glyphosate caused cancer or that regulatory determinations changed—the settlement was a business decision to resolve litigation risk. For claimants, the settlement provided a structured process for filing claims and receiving compensation based on factors like exposure duration, cancer type, and medical documentation. However, this settlement also capped potential individual awards, meaning someone filing a claim through the settlement process would generally receive less than if they had won a jury trial like Johnson did.
Important Limitations and What Claimants Need to Know
One major limitation of the Johnson verdict is that it does not automatically prove that glyphosate causes cancer in all users. The jury found that Monsanto failed to warn Johnson about risks and acted with malice—a company-specific finding about its conduct, not a universal statement about the chemical’s toxicity. Someone claiming injury from Roundup exposure must still prove, through medical evidence and expert testimony, that their specific cancer was caused by glyphosate exposure and not by other factors like genetics, smoking, or other environmental exposures. This is a high bar, and not all claims succeed even after Johnson’s precedent.
Additionally, statutes of limitations affect who can file a claim. Most jurisdictions require that a lawsuit be filed within a certain number of years after diagnosis or discovery of the link between exposure and injury. Someone who was exposed to Roundup decades ago but has only recently been diagnosed with cancer might still have options, but someone who knew they had cancer years ago and waited too long to file could be barred from recovery. Another critical warning: the Johnson settlement and other Roundup settlements typically require proof of actual exposure and a qualifying cancer diagnosis. Claims based on theoretical exposure or precancerous conditions generally do not qualify, and fraudulent claims can result in criminal prosecution.
The Role of Scientific Evidence and Expert Testimony
The Johnson case hinged significantly on expert testimony about the science of glyphosate and cancer risk. Both sides presented respected scientists and epidemiologists who offered opinions about whether glyphosate could cause non-Hodgkin’s lymphoma. The jury found the plaintiff’s experts more credible than Monsanto’s experts, particularly regarding the interpretation of existing research and the significance of Johnson’s specific exposure history.
This illustrates a practical point: in herbicide injury cases, the quality and credibility of scientific experts can determine the outcome, even when regulatory agencies have reached different conclusions. The jury also considered evidence about Monsanto’s internal practices regarding its own scientists and research. Documents revealed that Monsanto had a practice of having external scientists serve as the public face of favorable research while Monsanto employees conducted the actual work behind the scenes—a strategy designed to create the appearance of independent confirmation. This “ghost-writing” controversy contributed to the jury’s assessment that the company had acted with malice and deception.
The Bayer Settlement and Current Status of Roundup Claims
After the Johnson verdict and subsequent adverse rulings, Bayer and Monsanto agreed to the $10.9 billion settlement in 2020, which covers three separate settlement programs: an economic loss settlement (for those who purchased Roundup but were not injured), a medical monitoring settlement (for those with exposure but no current diagnosis), and a personal injury settlement (for those with diagnosed cancers allegedly caused by glyphosate exposure). The settlement was designed to provide faster resolution for claimants compared to waiting for individual trials, though individual awards through settlement are typically smaller than potential jury verdicts. Looking forward, the landscape has stabilized somewhat, but new cases continue to emerge.
Some individuals who were excluded from the original settlement have pursued separate litigation, and international jurisdictions have reached different conclusions about glyphosate’s safety and Monsanto’s liability. The Johnson case established that U.S. juries are willing to hold companies accountable for failure to warn about risks, even when regulatory agencies maintain that products are safe—a principle that extends beyond herbicides to other consumer products and occupational exposures.
You Might Also Like
- T-Mobile $15.75 Million FCC Cybersecurity Settlement
- Bayer Roundup $11 Billion Prior Settlement Aggregate
- AT&T $13 Million FCC Supply Chain Data Breach Settlement
Open Settlements You Can Claim Now
Browse current class action settlements accepting claims — several require no proof of purchase: